Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 13, 2022 3:15pm
177 Views
Post# 35023149

RE:RE:Speaking to management

RE:RE:Speaking to managementI don't disagree with what you said. In this case, however, I am neither an optimist nor pessimist but just a reporter telling you what my friends said after their second encounter of the day with management. 

qwerty22 wrote:

"He told them there was no doubt that TH was a TH-1902 focused company. "


You're optimism versus my cynicism. That is always going to be his public statement right up until the day they pull the plug on the program. It can be no other way.

 

SPCEO1 wrote: I spoke to several other shareholders who had a call with management and their reaction to that call was much, much better than their initial reaction to this morning's call. Paul evidently wanted to take a victory lap for the team on all the non TH-1902 stuff the company has accomplished and that is why TH-1902 was less of a focus this morning. Also, they had nothing new they can speak about yet on TH-1902 so it was a good time to focus on the other aspects of TH. He told them there was no doubt that TH was a TH-1902 focused company. 

They all (three individuals) walked away from their meeting a lot more comfortable with the stock than they were earlier and were encouraged by what they heard. They said Paul and Christian were very straightforward in answering the tough questions they asked. So, while they got no additional facts it sounded like the tenor of the call was about 100% opposite of the call this morning.


 

 

 



<< Previous
Bullboard Posts
Next >>